$412 Million is the total value of Krensavage Asset Management, LLC's 16 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 37.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Buy | UNITED THERAPEUTICS CORP | $73,460,000 | +68.6% | 653,787 | +122.1% | 17.82% | +31.2% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $59,852,000 | +17.7% | 739,738 | -14.7% | 14.52% | -8.4% |
| AMGN | Buy | AMGEN INC | $44,567,000 | +193.0% | 261,420 | +198.8% | 10.81% | +128.0% |
| MCK | Buy | MCKESSON CORP | $41,048,000 | +108.1% | 291,392 | +130.4% | 9.96% | +62.0% |
| GILD | Buy | GILEAD SCIENCES INC | $39,354,000 | +14.9% | 522,003 | +9.2% | 9.55% | -10.6% |
| MRK | Buy | MERCK & CO. INC. | $30,081,000 | +235.2% | 552,254 | +246.3% | 7.30% | +160.9% |
| RTIX | Buy | RTI SURGICAL INC | $20,064,000 | +12.9% | 4,361,787 | +0.6% | 4.87% | -12.1% |
| IVC | Buy | INVACARE CORP | $19,395,000 | +3.9% | 1,114,658 | +0.6% | 4.70% | -19.1% |
| HYH | Buy | HALYARD HEALTH INC | $18,497,000 | +1.4% | 401,400 | +1.6% | 4.49% | -21.1% |
| SHPG | New | SHIRE PLC-ADR | $17,927,000 | – | 120,000 | +100.0% | 4.35% | – |
| New | SIEMENS HEALTHINEERS AG | $16,582,000 | – | 400,000 | +100.0% | 4.02% | – | |
| OFIX | Sell | ORTHOFIX INTERNATIONAL NV | $15,697,000 | -11.5% | 267,052 | -17.7% | 3.81% | -31.1% |
| CNMD | Sell | CONMED CORP | $10,381,000 | +23.8% | 163,924 | -0.4% | 2.52% | -3.7% |
| JNP | Sell | JUNIPER PHARMACEUTICALS INC | $3,378,000 | +58.3% | 332,838 | -24.4% | 0.82% | +23.3% |
| VXRT | New | VAXART INC | $1,366,000 | – | 256,973 | +100.0% | 0.33% | – |
| DRAD | Buy | DIGIRAD CORP | $552,000 | -39.5% | 356,347 | +0.6% | 0.13% | -52.8% |
| AVIR | Exit | AVIRAGEN THERAPEUTICS INC | $0 | – | -2,809,531 | -100.0% | -0.50% | – |
| SCMP | Exit | SUCAMPO PHARMACEUTICALS-CL A | $0 | – | -1,304,376 | -100.0% | -7.30% | – |
| Exit | BIOVERATIV INC | $0 | – | -730,260 | -100.0% | -12.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.